AIM ImmunoTech(AIM)
$0.15+0.01 (+7.25%)
AIM
AIM ImmunoTech financials statements
$0.15
At close:+0.01 (+7.25%)
Want to see AIM full AI Analyst Report?
AIM ImmunoTech (AIM) Ratios
1,084 Followers
AIM ImmunoTech Ratios
AIM's free cash flow for Q2 2026 was $2.75M. For the 2026 fiscal year, AIM's free cash flow was increased by $35.00K and operating cash flow was $2.72M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Dec 24 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.53 | 0.44 | 1.68 | 26.69 | 74.61 |
| Quick Ratio | 0.53 | 0.44 | 1.72 | 26.69 | 74.61 |
| Cash Ratio | 0.15 | 0.18 | 0.63 | 19.88 | 47.69 |
| Solvency Ratio | -0.88 | -1.72 | -3.14 | -9.84 | -22.38 |
| Operating Cash Flow Ratio | -1.76 | -1.56 | -2.46 | -11.84 | -20.75 |
| Short-Term Operating Cash Flow Coverage | -2.88 | -6.45 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -12.27M | $ -5.75M | $ 5.41M | $ 34.30M | $ 49.39M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.85 | 0.34 | 0.04 | 0.02 | 0.00 |
| Debt-to-Equity Ratio | -0.50 | -2.22 | 0.07 | 0.02 | 0.00 |
| Debt-to-Capital Ratio | -1.00 | 1.82 | 0.07 | 0.02 | 0.00 |
| Long-Term Debt-to-Capital Ratio | -0.10 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.59 | -6.51 | 1.89 | 1.05 | 1.01 |
| Debt Service Coverage Ratio | -2.81 | -5.70 | 0.00 | 0.00 | -272.91 |
| Interest Coverage Ratio | -12.96 | -33.80 | 0.00 | 0.00 | -281.16 |
| Debt to Market Cap | 2.58 | 0.08 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 3.53 | 2.28 | 1.48 | 1.74 | 0.46 |
| Net Debt to EBITDA | -0.31 | -0.08 | 0.16 | 1.32 | 1.75 |
| Profitability Margins | |||||
| Gross Profit Margin | -284.09% | 81.76% | 79.21% | 400.71% | -529.63% |
| EBIT Margin | -14938.64% | -9844.12% | -14337.62% | -13790.78% | -14118.52% |
| EBITDA Margin | -14700.00% | -9699.41% | -14219.80% | -14091.49% | -13544.44% |
| Operating Profit Margin | -11961.36% | -11630.59% | -15800.00% | -14129.65% | -13954.07% |
| Pretax Profit Margin | -15861.36% | -10188.24% | -14337.62% | -13790.78% | -14168.15% |
| Net Profit Margin | -15861.36% | -10188.24% | -14337.62% | -13790.78% | -14168.15% |
| Continuous Operations Profit Margin | -15861.36% | -10188.24% | -14337.62% | -13790.78% | -14168.15% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 132.60% | 87.60% | 90.74% | 97.60% | 101.53% |
| Return on Assets (ROA) | -241.40% | -201.21% | -149.44% | -48.03% | -33.15% |
| Return on Equity (ROE) | 142.68% | 1310.14% | -283.00% | -50.55% | -33.63% |
| Return on Capital Employed (ROCE) | 2381.45% | 2132.90% | -297.47% | -50.92% | -33.03% |
| Return on Invested Capital (ROIC) | -313.55% | -1221.25% | -291.42% | -50.69% | -33.01% |
| Return on Tangible Assets | -338.70% | -287.99% | -169.69% | -50.44% | -34.32% |
| Earnings Yield | -763.13% | -59.59% | -135.48% | -130.55% | -43.92% |
| Efficiency Ratios | |||||
| Receivables Turnover | 12.57 | 0.00 | 0.17 | 0.08 | 0.08 |
| Payables Turnover | 0.21 | 0.00 | 0.01 | -1.12 | 4.29 |
| Inventory Turnover | 0.00 | 0.00 | -0.14 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.20 | 0.23 | 0.25 | 0.14 | 0.03 |
| Asset Turnover | 0.02 | 0.02 | 0.01 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | -0.02 | 0.62 | 0.01 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1731.17 | -75154.68 | -56477.86 | 4663.12 | 4351.75 |
| Days of Sales Outstanding | 29.03 | 0.00 | 2139.41 | 4338.58 | 4436.78 |
| Days of Inventory Outstanding | 0.00 | 0.00 | -2624.52 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1760.21 | 75154.68 | 55992.74 | -324.54 | 85.02 |
| Operating Cycle | 29.03 | 0.00 | -485.12 | 4338.58 | 4436.78 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -6.77 | -9.64 | -43.77 | -33.53 | -29.50 |
| Free Cash Flow Per Share | -7.00 | -9.65 | -44.98 | -34.09 | -30.84 |
| Dividend Paid and CapEx Coverage Ratio | -28.99 | -827.11 | -36.35 | -59.44 | -22.06 |
| Capital Expenditure Coverage Ratio | -28.99 | -827.11 | -36.35 | -59.44 | -22.06 |
| Operating Cash Flow Coverage Ratio | -2.24 | -5.06 | -29.62 | -19.24 | -93.72 |
| Operating Cash Flow to Sales Ratio | -124.51 | -87.58 | -105.28 | -114.24 | -103.44 |
| Free Cash Flow Yield | -619.72% | -51.28% | -102.22% | -109.97% | -33.52% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.13 | -1.68 | -0.74 | -0.77 | -2.28 |
| Price-to-Sales (P/S) Ratio | 20.78 | 170.97 | 105.83 | 105.64 | 322.61 |
| Price-to-Book (P/B) Ratio | -0.19 | -21.99 | 2.09 | 0.39 | 0.77 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.16 | -1.95 | -0.98 | -0.91 | -2.98 |
| Price-to-Operating Cash Flow Ratio | -0.17 | -1.95 | -1.01 | -0.92 | -3.12 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | 0.03 | -0.02 | -4.42 | 0.21 |
| Enterprise Value Multiple | -0.45 | -1.84 | -0.58 | 0.57 | -0.63 |
| Enterprise Value | 5.79M | 30.31M | 16.66M | -11.32M | 11.61M |
| EV to EBITDA | -0.45 | -1.84 | -0.58 | 0.57 | -0.63 |
| EV to Sales | 65.84 | 178.27 | 82.46 | -80.29 | 85.99 |
| EV to Free Cash Flow | -0.51 | -2.03 | -0.76 | 0.69 | -0.80 |
| EV to Operating Cash Flow | -0.53 | -2.04 | -0.78 | 0.70 | -0.83 |
| Tangible Book Value Per Share | -7.07 | -2.54 | 16.30 | 76.02 | 115.98 |
| Shareholders’ Equity Per Share | -6.04 | -0.86 | 21.06 | 80.06 | 120.15 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.05 | 0.11 | 0.42 | 0.29 | 0.29 |
| Net Income Per Share | -8.62 | -11.21 | -59.61 | -40.47 | -40.40 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.06 | 1.03 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 44.59 | 36.45 | 54.08 | 49.57 | 56.83 |
| SG&A to Revenue | 87.50 | 80.67 | 104.64 | 92.72 | 64.24 |
| Stock-Based Compensation to Revenue | 0.68 | 4.04 | 1.20 | 6.77 | 11.61 |
| Income Quality | 0.78 | 0.86 | 0.73 | 0.83 | 0.73 |
Currency in USD
